JNDA Submission Represents First Regulatory Submission for Marketing Approval of Vadadustat CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jul. 23, 2019– Akebia Therapeutics, Inc. (Nasdaq: AKBA), today announced that Mitsubishi Tanabe Pharma Corporation (MTPC), its development and commercialization collaboration partner in Japan for vadadustat, Akebia’s investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), has submitted a Japanese New Drug Application (JNDA) to the Ministry of Health, Labor and Welfare in Japan for manufacturing and…
Read More
(Credit: Pietro Artoni/Boston Children’s Hospital) Autism and other neurodevelopmental disorders often aren’t diagnosed until a child is a few years of age, when behavioral interventions and speech/occupational therapy become less effective. But new research this week in PNAS suggests that two simple, quantifiable measures — spontaneous fluctuations in pupil dilation or heart rate — could enable much earlier diagnosis of Rett syndrome and possibly other…
Read More
3D InSight™ Human Liver Disease platform provides the most physiologically relevant testing environment for efficacy and safety InSphero 07/19/2019 Schlieren, Switzerland – July 17, 2019   InSphero AG today announced a breakthrough in 3D cell technology for drug discovery and safety testing with the launch of its 3D InSight™ Human Liver Disease Discovery Platform for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The…
Read More

A New Spin on an Old Question

DNA helicopters offer insight into how biological machines power living things BY Caitlin McDermott-MurphyHarvard Correspondent For decades, researchers have chased ways to study how biological machines power living things. Every mechanical movement — from contracting a muscle to replicating DNA — relies on energy-fueled molecular motors that take tiny, near-undetectable steps. Trying to see these movements is like trying to watch…
Read More
Glioblastoma is an incurable brain cancer that kills most patients less than two years after diagnosis. The disease is difficult to treat largely because tumors each contain multiple kinds of cells. The aggressive brain cancer can also vastly differ between patients, so much so that researchers debate whether glioblastoma should be considered a single disease. A new study may help…
Read More
Throughout the animal kingdom, males and females frequently exhibit sexual dimorphism: differences in characteristic traits that often make it easy to tell them apart. In mammals, one of the most common sex-biased traits is size, with males typically being larger than females. This is true in humans: Men are, on average, taller than women. However, biological differences among males and…
Read More
Boehringer Ingelheim has entered into a collaboration and global license agreement for Bridge Biotherapeutics’s autotaxin inhibitor BBT-877 to be developed for fibrosing interstitial lung diseases including IPF With this new partnership Boehringer Ingelheim further expands its commitment to bring new treatments to patients with fibrosing interstitial lung diseases including IPF Bridge Biotherapeutics stands to receive up to more than EUR…
Read More
BURLINGTON, Mass. and CAMBRIDGE, Mass., July 18, 2019 /PRNewswire/ — MilliporeSigma and the Broad Institute of MITand Harvard today announced an agreement to offer non-exclusive licenses to CRISPR intellectual property (IP) under their respective control for use in commercial research and product development. “Together with the Broad Institute, we are simplifying the path to licensing CRISPR technology, which will make it more widely available to the global research and…
Read More
Series A Round Led by Vida Ventures and Omega Funds Company Platform Using Small Molecule Microarray (SMM) Technology has the Potential to Unlock Historically Undruggable Targets July 18, 2019 06:00 AM Eastern Daylight Time SAN MATEO, Calif. & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Kronos Bio, Inc. (Kronos), a Two River portfolio company, today announced it has closed a $105 million Series A Preferred…
Read More
Woburn-based hearing loss startup Frequency Therapeutics has found its first partner, but it will give up most of its commercial rights in a deal announced this week. Japanese firm Astellas Health will join Frequency Therapeutics as it steers its first treatment for the most common cause of hearing loss through the clinic. In exchange for $80 million upfront and a…
Read More